A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in Adults with Type 1 Diabetes
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Jun 2018
At a glance
- Drugs Insulin lispro (Primary) ; Insulin degludec; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms PRONTO-T1D
- Sponsors Eli Lilly
- 12 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Apr 2018 Planned End Date changed from 26 Sep 2019 to 21 Aug 2019.
- 19 Jul 2017 Status changed from not yet recruiting to recruiting.